Glaukos proudly celebrates a significant global milestone—more than 3 million interventional glaucoma implants worldwide – highlighting the company’s transformative impact on the treatment of glaucoma.
As the pioneer of Micro-Invasive Glaucoma Surgery (MIGS), Glaukos has helped redefine the glaucoma treatment paradigm by introducing innovative, dropless platforms designed to improve clinical outcomes and help preserve vision for patients living with this chronic, sight-threatening disease.
Reaching the 3 million implant milestone represents more than a global achievement. It reflects the growing confidence of surgeons around the world—and particularly across the Asia-Pacific region—in interventional glaucoma and in Glaukos as a trusted, long-term innovation partner. The milestone underscores the strong collaboration between Glaukos and the ophthalmic community in advancing earlier, more proactive glaucoma care.
Since its introduction, iStent® technology has empowered surgeons to intervene earlier in the disease continuum, reducing reliance on topical medications improve quality of life for patients.
Looking ahead, Glaukos remains firmly committed to continued innovation across glaucoma, corneal health, and retinal disease. Guided by their mission to truly transform vision, Glaukos will continue pioneering novel therapies and platforms designed to meaningfully advance the standard of care and improve outcomes for patients worldwide.
“Three million implants means millions of eyes where glaucoma is being managed differently — earlier, less invasively, and with greater precision. That’s the real milestone. Glaukos has been at the center of this transformation, giving ophthalmologists around the world practical, proven tools to change the trajectory of this disease, and I’m proud to be part of that effort.” – Ike Ahmed
Source: Glaukos Corporation
